315 related articles for article (PubMed ID: 17761758)
1. Isolation and characterization of mesoangioblasts from facioscapulohumeral muscular dystrophy muscle biopsies.
Morosetti R; Mirabella M; Gliubizzi C; Broccolini A; Sancricca C; Pescatori M; Gidaro T; Tasca G; Frusciante R; Tonali PA; Cossu G; Ricci E
Stem Cells; 2007 Dec; 25(12):3173-82. PubMed ID: 17761758
[TBL] [Abstract][Full Text] [Related]
2. Mesoangioblasts from facioscapulohumeral muscular dystrophy display in vivo a variable myogenic ability predictable by their in vitro behavior.
Morosetti R; Gidaro T; Broccolini A; Gliubizzi C; Sancricca C; Tonali PA; Ricci E; Mirabella M
Cell Transplant; 2011; 20(8):1299-313. PubMed ID: 21176400
[TBL] [Abstract][Full Text] [Related]
3. [The possible place of autologus cell therapy in facioscapulohumeral muscular dystrophy].
Desnuelle C; Sacconi S; Marolleau JP; Larghero J; Vilquin JT
Bull Acad Natl Med; 2005 Apr; 189(4):697-713; discussion 713-4. PubMed ID: 16245686
[TBL] [Abstract][Full Text] [Related]
4. Normal growth and regenerating ability of myoblasts from unaffected muscles of facioscapulohumeral muscular dystrophy patients.
Vilquin JT; Marolleau JP; Sacconi S; Garcin I; Lacassagne MN; Robert I; Ternaux B; Bouazza B; Larghero J; Desnuelle C
Gene Ther; 2005 Nov; 12(22):1651-62. PubMed ID: 15973444
[TBL] [Abstract][Full Text] [Related]
5. Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation.
Winokur ST; Chen YW; Masny PS; Martin JH; Ehmsen JT; Tapscott SJ; van der Maarel SM; Hayashi Y; Flanigan KM
Hum Mol Genet; 2003 Nov; 12(22):2895-907. PubMed ID: 14519683
[TBL] [Abstract][Full Text] [Related]
6. Cell therapy of primary myopathies.
Sampaolesi M; Biressi S; Tonlorenzi R; Innocenzi A; Draghici E; Cusella de Angelis MG; Cossu G
Arch Ital Biol; 2005 Sep; 143(3-4):235-42. PubMed ID: 16097501
[TBL] [Abstract][Full Text] [Related]
7. Severe phenotype in infantile facioscapulohumeral muscular dystrophy.
Klinge L; Eagle M; Haggerty ID; Roberts CE; Straub V; Bushby KM
Neuromuscul Disord; 2006 Oct; 16(9-10):553-8. PubMed ID: 16934468
[TBL] [Abstract][Full Text] [Related]
8. Quantitative MR imaging of individual muscle involvement in facioscapulohumeral muscular dystrophy.
Kan HE; Scheenen TW; Wohlgemuth M; Klomp DW; van Loosbroek-Wagenmans I; Padberg GW; Heerschap A
Neuromuscul Disord; 2009 May; 19(5):357-62. PubMed ID: 19329315
[TBL] [Abstract][Full Text] [Related]
9. FRG2, an FSHD candidate gene, is transcriptionally upregulated in differentiating primary myoblast cultures of FSHD patients.
Rijkers T; Deidda G; van Koningsbruggen S; van Geel M; Lemmers RJ; van Deutekom JC; Figlewicz D; Hewitt JE; Padberg GW; Frants RR; van der Maarel SM
J Med Genet; 2004 Nov; 41(11):826-36. PubMed ID: 15520407
[TBL] [Abstract][Full Text] [Related]
10. [Facioscapulohumeral muscular dystrophy. The spectrum of clinical manifestations and molecular genetic changes].
Krasnianski M; Neudecker S; Eger K; Schulte-Mattler W; Zierz S
Nervenarzt; 2003 Feb; 74(2):151-8. PubMed ID: 12596016
[TBL] [Abstract][Full Text] [Related]
11. Expression profile of FSHD supports a link between retinal vasculopathy and muscular dystrophy.
Osborne RJ; Welle S; Venance SL; Thornton CA; Tawil R
Neurology; 2007 Feb; 68(8):569-77. PubMed ID: 17151338
[TBL] [Abstract][Full Text] [Related]
12. RAGE-NF-kappaB pathway activation in response to oxidative stress in facioscapulohumeral muscular dystrophy.
Macaione V; Aguennouz M; Rodolico C; Mazzeo A; Patti A; Cannistraci E; Colantone L; Di Giorgio RM; De Luca G; Vita G
Acta Neurol Scand; 2007 Feb; 115(2):115-21. PubMed ID: 17212615
[TBL] [Abstract][Full Text] [Related]
13. Isolation and characterization of mesoangioblasts from mouse, dog, and human tissues.
Tonlorenzi R; Dellavalle A; Schnapp E; Cossu G; Sampaolesi M
Curr Protoc Stem Cell Biol; 2007 Dec; Chapter 2():Unit 2B.1. PubMed ID: 18785178
[TBL] [Abstract][Full Text] [Related]
14. Facioscapulohumeral muscular dystrophy. Phenotype-genotype correlation in patients with borderline D4Z4 repeat numbers.
Butz M; Koch MC; Müller-Felber W; Lemmers RJ; van der Maarel SM; Schreiber H
J Neurol; 2003 Aug; 250(8):932-7. PubMed ID: 12928911
[TBL] [Abstract][Full Text] [Related]
15. Abnormal expression of mu-crystallin in facioscapulohumeral muscular dystrophy.
Reed PW; Corse AM; Porter NC; Flanigan KM; Bloch RJ
Exp Neurol; 2007 Jun; 205(2):583-6. PubMed ID: 17451686
[TBL] [Abstract][Full Text] [Related]
16. Correction of the FSHD myoblast differentiation defect by fusion with healthy myoblasts.
Dib C; Bou Saada Y; Dmitriev P; Richon C; Dessen P; Laoudj-Chenivesse D; Carnac G; Lipinski M; Vassetzky YS
J Cell Physiol; 2016 Jan; 231(1):62-71. PubMed ID: 26218298
[TBL] [Abstract][Full Text] [Related]
17. Functional muscle impairment in facioscapulohumeral muscular dystrophy is correlated with oxidative stress and mitochondrial dysfunction.
Turki A; Hayot M; Carnac G; Pillard F; Passerieux E; Bommart S; Raynaud de Mauverger E; Hugon G; Pincemail J; Pietri S; Lambert K; Belayew A; Vassetzky Y; Juntas Morales R; Mercier J; Laoudj-Chenivesse D
Free Radic Biol Med; 2012 Sep; 53(5):1068-79. PubMed ID: 22796148
[TBL] [Abstract][Full Text] [Related]
18. Skeletal muscle regeneration in facioscapulohumeral muscular dystrophy is correlated with pathological severity.
Banerji CRS; Henderson D; Tawil RN; Zammit PS
Hum Mol Genet; 2020 Sep; 29(16):2746-2760. PubMed ID: 32744322
[TBL] [Abstract][Full Text] [Related]
19. FSHD-like patients without 4q35 deletion.
Yamanaka G; Goto K; Ishihara T; Oya Y; Miyajima T; Hoshika A; Nishino I; Hayashi YK
J Neurol Sci; 2004 Apr; 219(1-2):89-93. PubMed ID: 15050443
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic challenges in facioscapulohumeral muscular dystrophy.
Sacconi S; Salviati L; Bourget I; Figarella D; Péréon Y; Lemmers R; van der Maarel S; Desnuelle C
Neurology; 2006 Oct; 67(8):1464-6. PubMed ID: 17060574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
